RxDoctor Payments Data

Stefanie Ehrlein

Adult Health · Mount Sinai, NYNPI 1639758923

Payments from drug & device makers

$2,052in general payments, 2019–2025

Across 38 payments — averaging $54.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$527
  • Esperion Therapeutics, Inc.$274
  • Amgen$271
  • Novo Nordisk$210
  • Boehringer Ingelheim$172
  • Relievant Medsystems, Inc.$146
  • plus $453 from 8 others

What the payments were for

  • Food & beverage$2,052100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,052 in reported general payments places this provider in the 80th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$60,216
Medicare patients
158
Services billed
793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin25$39,914
MounjaroTirzepatide13$19,236
XareltoRivaroxaban14$17,062
TradjentaLinagliptin11$15,582
RybelsusSemaglutide12$14,470
OzempicSemaglutide15$12,136
Levothyroxine Sodium123$2,716
Albuterol Sulfate HfaAlbuterol Sulfate81$2,228
Metoprolol Succinate96$1,445
Fluticasone Propionate125$1,409
Rosuvastatin Calcium83$1,047
Levocetirizine Dihydrochloride69$980
Azelastine Hcl48$953
Atorvastatin Calcium154$908
Duloxetine Hcl29$880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$172$55,49636 claims
Novo NordiskRybelsus, Ozempic$210$26,60627 claims
Johnson & JohnsonXarelto$31$17,06214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,828 adult health providers in New York.

Other adult health in Mount Sinai

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →